1
|
Medina S, Del Rio M, Hernanz A, Guaza C, De la Fuente M. Nitric oxide released by accessory cells mediates the gastrin-releasing peptide effect on murine lymphocyte chemotaxis. ACTA ACUST UNITED AC 2005; 131:46-53. [PMID: 15996770 DOI: 10.1016/j.regpep.2005.06.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2005] [Revised: 06/01/2005] [Accepted: 06/07/2005] [Indexed: 11/28/2022]
Abstract
Several neuropeptides, including gastrin-releasing peptide (GRP), modulate the immune response, specifically lymphocyte chemotaxis. In the present work the effect of GRP on the chemotaxis of murine lymphocytes from different immune locations in both, total leukocyte populations and populations depleted of adherent cells have been studied. Specificity of the GRP effect on chemotaxis using an antagonist of the GRP receptor, as well as the implication of nitric oxide (NO), using inhibitors of NO synthase and donors of NO, were investigated. The effects of GRP stimulating the chemotaxis of lymphocytes from peritoneum, axillary nodes and spleen and decreasing the chemotaxis from thymus were receptor-specific and disappeared in lymphocytes from populations depleted of adherent cells. NO synthase inhibitors blocked the GRP effect on lymphocyte chemotaxis, and this action was reversed in the presence of l-arginine. Thus, the effect of GRP on murine lymphocyte chemotaxis appears to be mediated by NO secreted by adherent cells.
Collapse
Affiliation(s)
- Sonia Medina
- Department of Animal Physiology, Faculty of Biology, Complutense University, Spain
| | | | | | | | | |
Collapse
|
2
|
Sun B, Schally AV, Halmos G. The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. REGULATORY PEPTIDES 2000; 90:77-84. [PMID: 10828496 DOI: 10.1016/s0167-0115(00)00114-2] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Bombesin-like peptides can function as autocrine or paracrine growth factors and stimulate the growth of various cancers. The antagonists of bombesin/gastrin-releasing peptide (GRP) suppress the proliferation of diverse tumors including ovarian cancer by mechanisms likely mediated by bombesin receptors. In this study, we used the reverse transcription-polymerase chain reaction (RT-PCR) method to evaluate the mRNA expression of three bombesin receptor subtypes: gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), in 22 specimens of human epithelial ovarian cancer and in two human ovarian cancer lines. Of the 22 ovarian cancer specimens analyzed, 17 tumors ( approximately 77%) expressed mRNA for GRPR, 19 ( approximately 86%) showed NMBR mRNA and six ( approximately 27%) revealed BRS-3 mRNA. Thus, 14 of 22 specimens ( approximately 64%) expressed mRNAs for both GRPR and NMBR, and five ( approximately 23%) expressed all three subtypes. The expression of GRPR appeared to be greater in poorly differentiated ovarian carcinomas. A higher incidence of BRS-3 expression was observed in samples with tumor Stage IV (4/4, 100%) compared with Stage III (1/17, approximately 6%). mRNA for both GRPR and NMBR was also detected in OV-1063 and UCI-107 human ovarian cancer xenografts, but BRS-3 was found only in OV-1063, which originated from a metastatic tumor. In addition, functional receptors for bombesin/GRP were found in eight of 11 ovarian cancer specimens investigated and in both ovarian cancer lines by receptor binding assay. Our study indicates that GRPR and NMBR are widely distributed in human ovarian carcinomas with BRS-3 being found in Stage IV tumors. Some approaches based on bombesin/GRP receptor antagonists or targeted bombesin analogs could be considered for treatment of ovarian cancers.
Collapse
Affiliation(s)
- B Sun
- Endocrine Polypeptide and Cancer Institute, Veterans Affairs Medical Center, 1601 Perdido Street, 70112-1262, New Orleans, LA, USA
| | | | | |
Collapse
|
3
|
Devin C, Bernad N, Cristau M, Artis-Noel AM, Heitz A, Fehrentz JA, Martinez J. Synthesis and biological evaluation of C-terminal hydroxamide analogues of bombesin. J Pept Sci 1999; 5:176-84. [PMID: 10323197 DOI: 10.1002/(sici)1099-1387(199904)5:4<176::aid-psc189>3.0.co;2-t] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Bombesin pseudo-peptide analogues containing a hydroxamide function on the C-terminal part of the molecule, e.g. H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-NHOBzl 1 and H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-NHOH 2 were synthesized. These compounds were tested for their ability to recognize the bombesin receptor on rat pancreatic acini and on 3T3 cells, to stimulate (i) amylase secretion from rat pancreatic acini and (ii) accumulation of tritiated thymidine in 3T3 cells. Compounds 1 and 2 were able to recognize bombesin receptors on both models with high affinity (Ki = 7 +/- 2 and 5.8 +/- 0.9 nM on rat pancreatic acini, and Ki = 4.1 +/- 1.2 and 7.7 +/- 1.9 nM on 3T3 cells, respectively). Interestingly, compound 1 behaved as a potent agonist in stimulating amylase secretion from rat pancreatic acini and is able to stimulate thymidine accumulation in 3T3 cells, while compound 2 was able to potently antagonize bombesin-stimulated amylase secretion (Ki = 22 +/- 5 nM) in rat pancreatic acini and had no proper effect on 3T3 cells; however, it was able to inhibit bombesin-stimulated thymidine accumulation in 3T3 cells with high potency (Ki = 1.6 +/- 0.6 nM).
Collapse
Affiliation(s)
- C Devin
- Laboratoire des Amino-acides, Peptides et Protéines, Faculté de Pharmacie, Montpellier, France
| | | | | | | | | | | | | |
Collapse
|
4
|
Condamine E, Chapdeleine G, Demarcy L, Duclos JF, Davoust D, Llinares M, Azay J, Martinez J, Chapelle S. Biological activity and three-dimensional structure of an agonist analog of bombesin. THE JOURNAL OF PEPTIDE RESEARCH : OFFICIAL JOURNAL OF THE AMERICAN PEPTIDE SOCIETY 1998; 51:55-64. [PMID: 9495592 DOI: 10.1111/j.1399-3011.1998.tb00417.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
JMV635, a nonapeptide analog of the active terminal nonapeptide segment of bombesin, was tested for its ability to stimulate in vitro amylase release from rat pancreatic acinar cells and to inhibit the binding of gastrin-releasing peptide to rat pancreatic acini. It was found to be a full agonist of bombesin and to recognize the bombesin receptor with moderate potency. The NMR proton assignments of JMV635 were achieved, and the conformations of JMV635 in aqueous solution and in trifluoroethanol at 297 K were determined using two-dimensional COSY, HOHAHA, NOESY and ROESY experiments. In trifluoroethanol, JMV635, like the active part of bombesin, showed a partial alpha-helical structure. These results were confirmed by circular dichroism and refined by restrained molecular dynamic methods. Structure calculations, using the distance and angle restraints obtained from NMR data on JMV635, gave a total of 75 structures which could be aligned to a root mean square deviation of the bond length of 0.007 A and of the valence angle of 1.55 degrees for the backbone atoms of the amino acid residues. The conformation is a well-defined right-handed alpha-helix in the C-terminal Q2-G6 segment and is less structured in the three C-terminal residues.
Collapse
Affiliation(s)
- E Condamine
- Institut Fédératif de Recherche Multidisciplinaire sur les Peptides, UPRESA CNRS 6014, UFR des Sciences, Université de Rouen, Mont-Saint-Aignan, France
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Llinares M, Devin C, Azay J, Bergé G, Fehrentz JA, Martinez J. Syntheses and biological activities of bombesin analogs modified in the C-terminal dipeptide part. Eur J Med Chem 1997. [DOI: 10.1016/s0223-5234(99)80063-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Affiliation(s)
- R de Castiglione
- Farmitalia Carlo Erba (now Pharmacia), Research Centre, Nerviano (MI), Italy
| | | |
Collapse
|
7
|
Affiliation(s)
- S R Preston
- Academic Unit of Surgery, St. James's University Hospital, Leeds, UK
| | | | | |
Collapse
|
8
|
Groot K, Horvàth JE, Cai RZ, Schally AV. Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH 1995; 45:561-6. [PMID: 7558587 DOI: 10.1111/j.1399-3011.1995.tb01320.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Bombesin-like and GRP-like peptides may act as autocrine growth factors in the proliferation of some cancers. A pseudononapeptide bombesin antagonist, [D-Tpi6,Leu13 psi(CH2NH)-Leu14]bombesin(6-14), and related analogs synthesized in our laboratory significantly inhibit tumor growth in various cancer models. A radio-immunoassay (RIA), suitable for determination of RC-3095 and its congeners in unextracted serum, was developed in order to facilitate further experimental and clinical evaluation of this bombesin/GRP receptor antagonist for the treatment of various tumors. Antibodies were generated against RC-3095 and Des-Tpi1-RC-3095, conjugated to bovine serum albumin with glutaraldehyde. Antiserum JH-631b was selected for further experiments based on the antibody characterization. At an antiserum dilution of 1:189,000, this antibody bound approximately 50% of 7 fmol of added radiolabeled Tyr1-RC-3095. The antibody crossreacted with C-terminal fragments of RC-3095. Fragments without the C-terminus and naturally existing peptides of the bombesin family or structurally unrelated peptides did not cross-react. The minimum detectable dose of RC-3095 was 0.4 pg/tube. Intra- and interassay coefficients of variation ranged from 3.2 to 4.4% and from 5.6 to 12.8%, respectively. The RIA is suitable for direct determination of RC-3095 in serum. The RIA should be of value for monitoring levels of this analog in serum during long-term therapy.
Collapse
Affiliation(s)
- K Groot
- Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana, USA
| | | | | | | |
Collapse
|
9
|
Del Rio M, De la Fuente M. Chemoattractant capacity of bombesin, gastrin-releasing peptide and neuromedin C is mediated through PKC activation in murine peritoneal leukocytes. REGULATORY PEPTIDES 1994; 49:185-93. [PMID: 8140272 DOI: 10.1016/0167-0115(94)90140-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Bombesin-like peptides have been recently shown to regulate immune functions. In the present work, we have studied their action as chemoattractants for murine peritoneal macrophages and lymphocytes. The results showed a significant increase in the number of cells that migrate when they are exposed to a gradient of bombesin, gastrin-releasing peptide (GRP) or neuromedin C (from 10(-8) to 10(-12) M). The most effective of the three neuropeptides studied was GRP, even more than formyl-Met-Leu-Phe peptide (FMLP), an established leukocyte chemoattractant. GRP action was mediated through specific cell receptors as it was significantly reduced in presence of a competitive and specific bombesin receptor antagonist. In the presence of retinal, a protein kinase C (PKC) inhibitor, the chemoattractant capacity of GRP was considerably reduced. In order to investigate further the mechanism of action involved in the GRP effect, we measured PKC activity. Peritoneal cells incubated with GRP experimented an increase in PKC activity to the same extent of that produced by the PKC activator phorbol myristate acetate (PMA). These data prove that bombesin-like peptides are potent chemoattractants for murine peritoneal macrophages and lymphocytes, and that their action is at least in part mediated through PKC activation.
Collapse
Affiliation(s)
- M Del Rio
- Departamento de Fisiología Animal, Facultad de CC. Biológicas, Unlversidad Complutense, Madrid, Spain
| | | |
Collapse
|
10
|
Bitar KN, Zhu XX. Expression of bombesin-receptor subtypes and their differential regulation of colonic smooth muscle contraction. Gastroenterology 1993; 105:1672-80. [PMID: 8253343 DOI: 10.1016/0016-5085(93)91062-m] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND Bombesin-related peptides show different potencies, suggesting the existence of at least two receptor subtypes. The aim of this study was to assess the relationship and contribution of each receptor subtype on smooth muscle contraction. METHODS The expression of bombesin-receptor subtype messenger RNA (mRNA) was examined in human and rabbit smooth muscle from the rectosigmoid colon, and the contribution of each of the receptor subtypes to smooth muscle contraction was investigated by blocking mRNA translation of either neuromedin B or gastrin-releasing peptide (GRP) receptor subtype or of both. RESULTS Neuromedin B and GRP receptor mRNAs were detected in human and rabbit colonic smooth muscle cells. Incubation with neuromedin B receptor antisense oligonucleotides inhibited the neuromedin B-induced contraction, whereas incubation with GRP receptor antisense oligonucleotides inhibited the GRP-induced contraction. Incubation with GRP plus neuromedin B receptor antisense oligonucleotides inhibited the contractile response induced by bombesin, neuromedin B, and GRP. CONCLUSIONS Distinct neuromedin B and GRP receptor subtypes are present on smooth muscle cells of the rectosigmoid colon, and bombesin interacts with both neuromedin B and GRP receptors, resulting in a complex contraction that is sustained in nature.
Collapse
Affiliation(s)
- K N Bitar
- Department of Pediatrics, University of Michigan Medical School, Ann Arbor
| | | |
Collapse
|
11
|
Olsen UB, Weis JU, Suzdak P, Lundt BF, Madsen K, Thøgersen H, Johansen NL. Important role of C-terminal peptide bonds for endothelin receptor binding and activity. PHARMACOLOGY & TOXICOLOGY 1993; 73:60-2. [PMID: 8234195 DOI: 10.1111/j.1600-0773.1993.tb01960.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- U B Olsen
- Department of Pharmacology, Novo Nordisk CNS-R&D, Måløv, Denmark
| | | | | | | | | | | | | |
Collapse
|
12
|
Szepeshazi K, Schally AV, Groot K, Halmos G. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. Int J Cancer 1993; 54:282-9. [PMID: 8387464 DOI: 10.1002/ijc.2910540220] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Female Syrian golden hamsters with N-nitroso-bis (2-oxopropyl) amine (BOP)-induced pancreatic cancers were treated for 2 months with bombesin/gastrin-releasing peptide (GRP) antagonist D-Tpi6,Leu13 psi(CH2NH)Leu14 bombesin(6-14) (RC-3095). Bombesin and GRP(14-27) were also administered alone and in combination with the antagonist RC-3095. RC-3095 exerted a dose-dependent inhibitory effect on growth of pancreatic cancers. The number of animals with pancreatic cancers was significantly lower in the group treated with 60 micrograms/day of RC-3095 and the weight of tumorous pancreata was reduced. Administration of bombesin or GRP alone did not stimulate the growth of pancreatic tumors and, in fact, had a slightly suppressive effect on cancers which was significant only in Experiment I. Bombesin and GRP (14-27) given together with RC-3095 did not nullify the inhibitory effect of the antagonist on pancreatic cancer growth. Actually, a greater inhibition of pancreatic tumors was observed after administration of RC-3095 together with bombesin or GRP, than with RC-3095 alone. The mechanism of action of bombesin, GRP, and bombesin antagonists on pancreatic cancers appears to be complex. The inhibitory effect of bombesin antagonists on pancreatic cancer growth was accompanied by a decrease in the binding capacity of EGF receptors in tumor membranes. Administration of bombesin also caused a down-regulation of EGF receptors and the greatest decrease in binding capacity of EGF receptors was observed after treatment with RC-3095 in combination with GRP. Inhibition of pancreatic cancer can thus be tentatively explained by some common pathways in the action of bombesin, GRP and their antagonists, that could be mediated by interference with EGF-receptor mechanisms.
Collapse
Affiliation(s)
- K Szepeshazi
- Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, Tulane University School of Medicine, New Orleans, LA 70146
| | | | | | | |
Collapse
|
13
|
Jensen RT, Mrozinski JE, Coy DH. Bombesin receptor antagonists: different classes and cellular basis of action. Recent Results Cancer Res 1993; 129:87-113. [PMID: 8394597 DOI: 10.1007/978-3-642-84956-5_8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- R T Jensen
- National Institutes of Health, Bethesda, MD 20892
| | | | | |
Collapse
|
14
|
Milovanovic SR, Radulovic S, Groot K, Schally AV. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160. Prostate 1992; 20:269-80. [PMID: 1376910 DOI: 10.1002/pros.2990200403] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The effects of treatment with a bombesin receptor antagonist [D-Tpi6, Leu13 psi (CH2NH) Leu14]BN(6-14)(RC-3095) and the combination of an agonist of luteinizing hormone-releasing hormone [D-Trp6]-LH-RH and somatostatin analog D-Phe-Cys-Tyr-D-Trp-Lys-Val- Cys-Trp-NH2 (RC-160) were studied in nude mice bearing xenografts of the hormone-dependent human prostate tumor PC-82. During the 5 weeks of treatment, tumor growth was decreased in all treated groups compared with controls. Bombesin antagonist RC-3095 and the combination of [D-Trp6]-LH-RH and RC-160 caused a greater inhibition of tumor growth than [D-Trp6]-LH-RH or RC-160 alone as based on measurement of tumor volume and percentage change in tumor volume. The largest decrease in tumor weight was also seen in the groups treated with the bombesin antagonist and with the combination of RC-160 and [D-Trp6]-LH-RH. Serum prostatic-specific antigen levels were greatly decreased, and insulin-like growth factor I (IGF-I) as well as growth hormone levels were reduced in all treated groups. Specific binding sites for [D-Trp6]-LH-RH, epidermal growth factor (EGF), IGF-I, and somatostatin (SS-14) were found in the tumor membranes. Receptors for EGF were significantly down-regulated by treatment with the bombesin antagonist or RC-160. Combination of LH-RH agonists with somatostatin analog RC-160 might be considered for improvement of hormonal therapy for prostate cancer. The finding that bombesin antagonist RC-3095 inhibits the growth of PC-82 prostate cancer suggests the merit of further studies to evaluate the possible usefulness of antagonists of bombesin in the management of prostatic carcinoma.
Collapse
Affiliation(s)
- S R Milovanovic
- Endocrine Institute, Veterans Administration Medical Center, New Orleans, LA 70146
| | | | | | | |
Collapse
|
15
|
Approaches to the synthesis of endothiopeptides: Synthesis of a thioamide-containing C-terminal bombesin nonapeptide. Tetrahedron 1992. [DOI: 10.1016/s0040-4020(01)89436-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
16
|
Zacharia S, Rossowski WJ, Jiang NY, Hrbas P, Ertan A, Coy DH. New reduced peptide bond substance P agonists and antagonists: effects on smooth muscle contraction. Eur J Pharmacol 1991; 203:353-7. [PMID: 1723044 DOI: 10.1016/0014-2999(91)90890-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Following the recent discovery of a new substance P (SP) competitive pancreatic acini cell receptor antagonist containing a reduced peptide bond in place of the C-terminal peptide bond, a new series of full chain and short chain (heptapeptide and hexapeptide) substance P analogues have been prepared in which one of the C-terminal-region peptide bonds has been replaced by CH2NH or CH2O groups. They were compared for their ability to recognize NK1 and/or NK2 tachykinin receptor binding sites on guinea pig ileum and rat duodenum smooth muscle preparations, respectively. It was found that all full sequence SP pseudopeptides were agonists with much reduced bioactivity in both tested systems and, in addition, [Gly9 psi(CH2NH)Leu10,Leu11]SP was found to be a relatively selective agonist for NK1 binding sites. Substitution of leucine at position 11 of SP heptapseudopeptides with phenylalanine generated a pseudopeptide with weak agonist activity when Gln at position 5 was replaced by D-Phe, or antagonists when this residue was replaced by D-Nal or D-Cpa. [Leu10 psi(CH2NH)Leu11]SP-(6-11) with Gln at position 6 substituted by D-Phe was a relatively stronger antagonist in both assay systems. These results suggest that, as with several other peptide systems of late, manipulation of the peptide bonds in SP can produce receptor antagonists which in some cases approach the potency of the classic spantide series and, furthermore, that the approach might be used to induce NK receptor specificity in both agonist and antagonist analogs.
Collapse
Affiliation(s)
- S Zacharia
- Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112
| | | | | | | | | | | |
Collapse
|
17
|
Gawlak SL, Kiener PA, Braslawsky GR, Greenfield RS. Homodimeric forms of bombesin act as potent antagonists of bombesin on Swiss 3T3 cells. Growth Factors 1991; 5:159-70. [PMID: 1662974 DOI: 10.3109/08977199109000280] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Two Lys3-bombesin dimers were prepared by crosslinking epsilon-amino groups Lys3-bombesin with noncleavable (glutaraldehyde) and cleavable [dimethyl-3,3'-dithiobispropionimidate (DTBP)] crosslinkers. The dimers were purified by HPLC ion-exchange chromatography and were shown to have retained immunoreactivity with an anti-bombesin monoclonal antibody directed against the C-terminal binding region of bombesin. The glutaraldehyde cross-linked bombesin dimer specifically inhibited binding of 125I-GRP to its receptor on Swiss 3T3 cells. Bombesin, at 0.6-60 nM induced mitogenesis in quiescent Swiss 3T3 cells, whereas, incubation of cells with the glutaraldehyde bombesin dimer at concentrations up to 124 nM did not. In competition assays, the bombesin dimer exhibited a dose dependent inhibition of bombesin-induced mitogenic activity and intracellular Ca++ mobilization. The bombesin dimer was 100 to 1000-fold more potent than D-Phe12Leu14-bombesin and D-Phe12bombesin, respectively, in inhibiting bombesin-induced mitogenesis on quiescent Swiss 3T3 cells. Similarly, the DTBP-bombesin dimer was not mitogenic to Swiss 3T3 cells, however, cleavage of the disulfide crosslinker with DTT of cell bound DTBP dimer restored mitogenic activity. Finally, the glutaraldehyde bombesin dimer also inhibited growth of bombesin receptor positive H345 SCLC cells in vitro. These findings suggest that the dimeric forms of bombesin are potent antagonists of bombesin.
Collapse
Affiliation(s)
- S L Gawlak
- Bristol-Myers Squibb Co., Department of Immunology, Wallingford, CT 06492
| | | | | | | |
Collapse
|
18
|
Abstract
Bombesin and the mammalian-related peptides gastrin-releasing peptide (GRP), GRP and neuromedin B have been shown to have numerous actions in the CNS, gastrointestinal tract and on growth. However, the role of the peptides in various physiological processes has remained unclear because of the lack of potent antagonists. Recent in vitro studies have described four different classes of bombesin receptor antagonist, some of which are active in the nanomolar range and in vivo. Robert Jensen and David Coy describe recent insights into peptide structural determinants of biological activity. Evidence from structure-function studies have resulted in identification of some analogues that function as potent antagonists in all systems examined. Furthermore, various subtypes of bombesin receptors can now be differentiated by these various classes of antagonist.
Collapse
Affiliation(s)
- R T Jensen
- Cell Biology Section, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892
| | | |
Collapse
|
19
|
Coy D, Wang LH, Jiang NY, Jensen R. Short chain bombesin pseudopeptides with potent bombesin receptor antagonist activity in rat and guinea pig pancreatic acinar cells. Eur J Pharmacol 1990; 190:31-8. [PMID: 1963850 DOI: 10.1016/0014-2999(90)94109-b] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
A series of potent bombesin antagonists based on the reduced C-terminal peptide bond modification which in the past resulted in the first really potent antagonists are compared for effects on bombesin-stimulated amylase release from and binding to rat and guinea pig pancreatic acini. It was found that the original member of this series, [Leu13 psi (CH2NH)Leu14] bombesin, displayed partial agonist activity with 11% efficacy in the rat. More recent analogues of this type which were found previously to be even more potent pure antagonists in the guinea pig pancreas or 3T3 cells, exhibited similarly higher binding affinity for rat acini but displayed even higher residual partial agonist activity in the rat. For instance, [D-Phe6,Leu13 psi (CH2NH)Phe14]bombesin-(6-14) was one of the most potent bombesin antagonists known in the guinea pig and 3T3 cell systems but has 40% partial agonist activity in the rat. Several structural modification strategies were developed to remove rat partial agonist properties with retention of high antagonist potency in all systems tested. The most effective of these was the substitution of a Cl on the aromatic ring of the Phe residue (p-Cl-Phe, Cpa) in position 14 to give [D-Phe6,Leu13 psi (CH2NH)Cpa14]bombesin-(6-14). This had higher binding affinities for both rat and guinea pig pancreatic acini and was a pure antagonist on both cell types. Another effective method was alteration of the stereochemistry of the position 14 amino acid in [D-Phe6,Leu13 psi (CH2ND)D-Phe14]bombesin-(6-14) which had somewhat lowered binding affinities but pure antagonist properties.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- D Coy
- Department of Medicine, Tulane University Medical Center, New Orleans, LA 70112
| | | | | | | |
Collapse
|